Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

S Groschel, RF Schlenk, J Engelmann, Veronika Rockova, V Teleanu, MWM Kuhn, K Eiwen, C Erpelinck, Marije Havermans, M Lubbert, U Germing, IGH Schmidt-Wolf, Berna Beverloo, GJ Schuurhuis, GJ Ossenkoppele, B Schlegelberger, LF Verdonck, E Vellenga, G Verhoef, P VandenbergheT Pabst, M Bargetzi, J Krauter, A Ganser, Peter Valk, Bob Löwenberg, K Dohner, H Dohner, Ruud Delwel

Research output: Contribution to journalArticleAcademicpeer-review

84 Citations (Scopus)

Abstract

Purpose To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements. Patients and Methods We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis. Results We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS Conclusion Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR. J Clin Oncol 31:95-103. (c) 2012 by American Society of Clinical Oncology
Original languageUndefined/Unknown
Pages (from-to)95-103
Number of pages9
JournalJournal of Clinical Oncology
Volume31
Issue number1
DOIs
Publication statusPublished - 2013

Research programs

  • EMC MGC-02-96-01
  • EMC MM-02-41-03
  • EMC NIHES-01-66-01

Cite this